Additionally, the main adverse cardiovascular events of proteasome inhibitors, particularly carfilzomib, including heart failure, hypertension, ischemia, and atrial fibrillation (>18%) usually occur during the first three months of therapy and are more common among patients with elevated baseline levels of brain natriuretic peptide (BNP) or NT-proBNP [37,39]. This evidence concerns the gene NPPB and hypertensive disorder.